Article ; Online: Management einer persistierenden Kolitis nach erfolgreicher Immuntherapie eines nicht-kleinzelligen Karzinoms der Lunge.
Zeitschrift fur Gastroenterologie
2022 Volume 60, Issue 7, Page(s) 1124–1130
Abstract: Immune checkpoint inhibitors have shown remarkable efficacy as new-generation drugs in anti-tumor therapy. However, the nonspecific activation of the immune system leads to a number of adverse side effects, so-called immune-related adverse events (irAEs), ...
Title translation | Management of persistent colitis after successful immunotherapy for non-small cell carcinoma of the lung. |
---|---|
Abstract | Immune checkpoint inhibitors have shown remarkable efficacy as new-generation drugs in anti-tumor therapy. However, the nonspecific activation of the immune system leads to a number of adverse side effects, so-called immune-related adverse events (irAEs), including the occurrence of diarrhea and colitis in about one third of treated patients.Endoscopically and histologically, there is significant overlap of immune-mediated colitis with classic IBD, making differentiation difficult.Therapeutically, high-dose glucocorticoids are used in grade 3 (severe) to grade 4 (life-threatening) colitis, in addition to discontinuation of ICI therapy. Steroid-refractory cases (up to 42%) benefit from the TNF inhibitor infliximab. Vedolizumab, analogous to inflammatory bowel disease, represents second-line therapy for infliximab-refractory cases. Little data exist to date on the efficacy of tofacitinib in refractory cases.We describe the case and therapeutic management of severe and persistent immune-mediated colitis after successful immunochemotherapy with pembrolizumab in an 80-year-old man with metastatic non-small cell carcinoma of the lung and pre-existing colitis unclassified and other comorbidities. |
MeSH term(s) | Aged, 80 and over ; Carcinoma/drug therapy ; Colitis/chemically induced ; Colitis/diagnosis ; Colitis/therapy ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Immunologic Factors ; Immunotherapy/adverse effects ; Infliximab/therapeutic use ; Lung ; Male |
Chemical Substances | Immunologic Factors ; Infliximab (B72HH48FLU) |
Language | German |
Publishing date | 2022-01-18 |
Publishing country | Germany |
Document type | Case Reports ; Journal Article |
ZDB-ID | 201387-3 |
ISSN | 1439-7803 ; 0172-8504 ; 0044-2771 |
ISSN (online) | 1439-7803 |
ISSN | 0172-8504 ; 0044-2771 |
DOI | 10.1055/a-1652-2638 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 111: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.A 111/X: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.